Cassia Capital Partners’s AbbVie ABBV Stock Holding History

Cassia Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76M	Buy	6,991 +37	+0.5%	+$7.96K	0.85%	25
2026 Q1	$1.51M	Buy	6,954 +318	+5%	+$70.5K	0.78%	30
2025 Q4	$1.52M	Sell	6,636 -242	-4%	-$55.1K	0.82%	24
2025 Q3	$1.59M	Buy	6,878 +693	+11%	+$141K	0.87%	22
2025 Q2	$1.15M	Sell	6,185 -145	-2%	-$26.9K	0.69%	31
2025 Q1	$1.33M	Buy	6,330 +272	+4%	+$52.9K	0.83%	19
2024 Q4	$1.08M	Buy	6,058 +1,671	+38%	+$307K	0.69%	24
2024 Q3	$866K	Sell	4,387 -248	-5%	-$46.3K	0.57%	23
2024 Q2	$795K	Buy	4,635 +89	+2%	+$14.7K	0.52%	30
2024 Q1	$828K	Buy	4,546 +875	+24%	+$151K	0.55%	27
2023 Q4	$569K	Buy	3,671 +125	+4%	+$18.2K	0.47%	30
2023 Q3	$529K	Buy	3,546 +74	+2%	+$10.9K	0.43%	25
2023 Q2	$468K	Buy	3,472 +1,362	+65%	+$200K	0.37%	33
2023 Q1	$336K	Sell	2,110 -47	-2%	-$7.19K	0.27%	39
2022 Q4	$349K	Buy	+2,157	New	+$331K	0.29%	37

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cassia Capital Partners's ABBV Position: Q2 2026 in Review

Cassia Capital Partners increased its AbbVie (ABBV) stake by 0.53% in Q2 2026, buying an estimated $7.96K and bringing the position to 6,991 shares worth $1.76M. The position accounts for 0.85% of the portfolio, ranked #25.

Cassia Capital Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cassia Capital Partners held 6,991 shares of AbbVie worth $1.76M as of Q2 2026.
Cassia Capital Partners bought 37 AbbVie shares in Q2 2026, an estimated $7.96K.
AbbVie made up 0.85% of Cassia Capital Partners's portfolio in Q2 2026, its #25 holding.
Cassia Capital Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cassia Capital Partners's 13F filing for Q2 2026, filed 30 Jul 2026.